BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rasche L, Weinhold N, Morgan GJ, van Rhee F, Davies FE. Immunologic approaches for the treatment of multiple myeloma. Cancer Treat Rev 2017;55:190-9. [PMID: 28431262 DOI: 10.1016/j.ctrv.2017.03.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Guillerey C, Nakamura K, Pichler AC, Barkauskas D, Krumeich S, Stannard K, Miles K, Harjunpää H, Yu Y, Casey M, Doban AI, Lazar M, Hartel G, Smith D, Vuckovic S, Teng MW, Bergsagel PL, Chesi M, Hill GR, Martinet L, Smyth MJ. Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model. JCI Insight 2019;5:125932. [PMID: 31194697 DOI: 10.1172/jci.insight.125932] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
2 Shinde P, Melinkeri S, Santra MK, Kale V, Limaye L. Autologous Hematopoietic Stem Cells Are a Preferred Source to Generate Dendritic Cells for Immunotherapy in Multiple Myeloma Patients. Front Immunol 2019;10:1079. [PMID: 31164886 DOI: 10.3389/fimmu.2019.01079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Danhof S, Hudecek M, Smith EL. CARs and other T cell therapies for MM: The clinical experience. Best Pract Res Clin Haematol 2018;31:147-57. [PMID: 29909915 DOI: 10.1016/j.beha.2018.03.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
4 Baertsch MA, Goldschmidt H. [Multiple myeloma : What has been confirmed in therapy?]. Internist (Berl) 2017;58:1250-7. [PMID: 29098319 DOI: 10.1007/s00108-017-0337-6] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Siegel DS, Schiller GJ, Song KW, Agajanian R, Stockerl-Goldstein K, Kaya H, Sebag M, Samaras C, Malek E, Talamo G, Seet CS, Mouro J, Pierceall WE, Zafar F, Chung W, Srinivasan S, Agarwal A, Bahlis NJ. Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure. Br J Haematol 2020;188:501-10. [PMID: 31588567 DOI: 10.1111/bjh.16213] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
6 Jimenez-Zepeda VH, Duggan P, Neri P, Chaudhry A, Tay J, Bahlis N. Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution. Leuk Lymphoma 2018;59:1920-6. [PMID: 29160734 DOI: 10.1080/10428194.2017.1403026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
7 Lancman G, Lozada K, Athar N, Jacobs S, Doucette J, Cho HJ, Jagannath S, Madduri D, Parekh S, Richard S, Richter J, Chari A. Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma. Clin Lymphoma Myeloma Leuk 2021;21:e470-6. [PMID: 33716054 DOI: 10.1016/j.clml.2020.12.026] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Yang Y, Liu Z, Wang H, Zhang G. HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma. Front Oncol 2021;11:670673. [PMID: 34178656 DOI: 10.3389/fonc.2021.670673] [Reference Citation Analysis]
9 Wang B, Rajeeve S, Madduri D. Chimeric Antigen Receptor T-Cell Therapeutics for Multiple Myeloma: Moving Into the Spotlight. Cancer J 2021;27:205-12. [PMID: 34549909 DOI: 10.1097/PPO.0000000000000525] [Reference Citation Analysis]
10 Rasche L, Kortüm KM, Raab MS, Weinhold N. The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma. Int J Mol Sci 2019;20:E1248. [PMID: 30871078 DOI: 10.3390/ijms20051248] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
11 Li Z, Chen Y, Yang B, Song H, Chen W, Zhou H. Successful recovery of a patient with multiple myeloma from severe coronavirus disease 2019 (COVID-19) pneumonia during the first chemotherapy cycle: A case report. Exp Ther Med 2021;21:392. [PMID: 33680114 DOI: 10.3892/etm.2021.9823] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Franssen LE, Mutis T, Lokhorst HM, van de Donk NWCJ. Immunotherapy in myeloma: how far have we come? Ther Adv Hematol 2019;10:2040620718822660. [PMID: 30719268 DOI: 10.1177/2040620718822660] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
13 Gherardin NA, Loh L, Admojo L, Davenport AJ, Richardson K, Rogers A, Darcy PK, Jenkins MR, Prince HM, Harrison SJ, Quach H, Fairlie DP, Kedzierska K, McCluskey J, Uldrich AP, Neeson PJ, Ritchie DS, Godfrey DI. Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma. Sci Rep 2018;8:4159. [PMID: 29515123 DOI: 10.1038/s41598-018-22130-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 10.8] [Reference Citation Analysis]
14 Mochel JP, Ekker SC, Johannes CM, Jergens AE, Allenspach K, Bourgois-Mochel A, Knouse M, Benzekry S, Wierson W, LeBlanc AK, Kenderian SS. CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies. AAPS J 2019;21:50. [PMID: 30963322 DOI: 10.1208/s12248-019-0322-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
15 Lin C, Zhang J. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2018;1869:200-15. [DOI: 10.1016/j.bbcan.2018.01.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
16 Ma T, Shi J, Liu H. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma. Ann Hematol 2019;98:813-22. [PMID: 30693373 DOI: 10.1007/s00277-018-03592-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
17 Morgan GJ, Rasche L. Maintaining therapeutic progress in multiple myeloma by integrating genetic and biological advances into the clinic. Expert Rev Hematol 2018;11:513-23. [PMID: 29944024 DOI: 10.1080/17474086.2018.1489718] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
18 Kleber M, Ntanasis-Stathopoulos I, Terpos E. BCMA in Multiple Myeloma-A Promising Key to Therapy. J Clin Med 2021;10:4088. [PMID: 34575199 DOI: 10.3390/jcm10184088] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Ma T, Shi J, Xiao Y, Bian T, Wang J, Hui L, Wang M, Liu H. Study on the Relationship Between the Expression of B Cell Mature Antigen and the Classification, Stage, and Prognostic Factors of Multiple Myeloma. Front Immunol 2021;12:724411. [PMID: 34867949 DOI: 10.3389/fimmu.2021.724411] [Reference Citation Analysis]
20 Nikesitch N, Lee JM, Ling S, Roberts TL. Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance. Clin Transl Immunology 2018;7:e1007. [PMID: 29484184 DOI: 10.1002/cti2.1007] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
21 Braunstein M, Weltz J, Davies F. A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma. Expert Rev Hematol 2021;14:377-89. [PMID: 33769179 DOI: 10.1080/17474086.2021.1909469] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]